Structural mechanisms of TRPV6 inhibition by ruthenium red and econazole.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34725357.
- Also identified by DOI 10.1038/s41467-021-26608-x and PMC identifier 8560856.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
TRPV6 is a calcium-selective ion channel implicated in epithelial Ca<sup>2+</sup> uptake. TRPV6 inhibitors are needed for the treatment of a broad range of diseases associated with disturbed calcium homeostasis, including cancers. Here we combine cryo-EM, calcium imaging, and mutagenesis to explore molecular bases of human TRPV6 inhibition by the antifungal drug econazole and the universal ion channel blocker ruthenium red (RR). Econazole binds to an allosteric site at the channel's periphery, where it replaces a lipid. In contrast, RR inhibits TRPV6 by binding in the middle of the ion channel's selectivity filter and plugging its pore like a bottle cork. Despite different binding site locations, both inhibitors induce similar conformational changes in the channel resulting in closure of the gate formed by S6 helices bundle crossing. The uncovered molecular mechanisms of TRPV6 inhibition can guide the design of a new generation of clinically useful inhibitors.
Medical subject headings
- Antifungal Agents
- Calcium Channel Blockers
- Calcium Channels
- Econazole
- Ruthenium Red
- TRPV Cation Channels